The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials
Abstract
INTRODUCTION: Type 2 diabetes mellitus and hypercholesterolemia have proven to give an increased incidence of cardiovascular diseases (CVD). Recent studies have suggested that the natural alkaloid berberine could have pharmacological activities potentially useful in diabetes and hypercholesterolemia management. AREAS COVERED: The aim of this review is to evaluate the metabolic properties of the natural alkaloid berberine, and its potential application to the treatment of diabetes and CVD prevention. EXPERT OPINION: Berberine proved to be effective in improving glycemic control and lipid profile. The modern investigation on berberine pharmacological activity is actually developing and numerous scientific evidences are actually in progress and reported in international congresses. The near future perspective is the isolation or neo-synthesis of berberine analogs with a higher bioavailability. The anti-hyperlipidemic and anti-diabetic effects of berberine have to be related to markers of improvement in organ damage in humans; longer trials are needed to better evaluate the safety profile of the molecule, when administered alone or in association with other anti-hyperlipidemic or anti-diabetic drugs, especially in the European population.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Meta-analyses of randomized trials confirm significant reductions in glycated hemoglobin, fasting glucose and lipid profile with berberine [25,26,27,28]”
From Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification-A Narrative Review (2026) · cites this paper as [28]
In the citing paper
“Side effects from BBR are mild to moderate, mostly gastrointestinal (diarrhea, constipation, abdominal distension) and comparable in frequency to the control groups.”
From Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels? (2021) · cites this paper as [64]
Citations
Cites
1 retracted
Lan, T., Shen, X., Liu, P., Liu, W., Xu, S., Xie, X. S., Jiang, Q. L., Li, W., & Huang, H. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.07.012 · Cited by 80
RetractedIDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040
Ogurtsova, K., Fernandes, J. D. D. R., Huang, Y., Linnenkamp, U., Guariguata, L., Cho, N. H., Cavan, D. A., Shaw, J. E., & Makaroff, L. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.03.024 · Cited by 7,138
IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030
Whiting, D. R., Guariguata, L., Weil, C., & Shaw, J. E. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.10.029 · Cited by 4,018
Standards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan, H., et al. (2004) · Nature Medicine · doi:10.1038/nm1135 · Cited by 1,391
(2017) · Arzneimittelforschung · doi:10.1055/s-00000175 · Cited by 1,134
Efficacy of berberine in patients with type 2 diabetes mellitus
Yin, J., Xing, H., & Ye, J. (2008) · Metabolism · doi:10.1016/j.metabol.2008.01.013 · Cited by 801
Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine
Imanshahidi, M., & Hosseinzadeh, H. (2008) · Phytotherapy Research · doi:10.1002/ptr.2399 · Cited by 636
Research works printed but not linked: 12
- Birdsall TC, 1997, Altern Med Rev, 2, 94
- Lu SS, 2009, J Endocrinol, 200, 159
- Leng S, 2004, Acta Pharmacol Sin, 25, 496
- Wang SH, 2004, Zhongguo Zhong Xi Yi Jie He Za Zhi, 24, 926
- Han J, 2011, Med Sci Monit, 17, RA164
- Peychev L., 2005, Pharmacia, 52, 118
- Olmez E, 1992, Arzneimittelforschung, 42, 1095
- Ko WH, 2000, Eur J Pharmacol, 399, 187, 10.1016/S0014-2999(00)00339-3 · DOI
- Huang WM, 1992, Chin Med J, 105, 1014
- Cheng F, 2012, Int J Cardiol
- Xu MG, 2008, Cardiology, 112, 279
- Huang CG, 1991, Comun Inform Pharm, 9, 10
Cited by
Sorted by citations
Zhang, X., Zhao, Y., Xu, J., Xue, Z., Zhang, M., Pang, X., Zhang, X., & Zhao, L. (2015) · Scientific Reports · doi:10.1038/srep14405 · Cited by 630
Berberis Vulgaris and Berberine: An Update Review
Imenshahidi, M., & Hosseinzadeh, H. (2016) · Phytotherapy Research · doi:10.1002/ptr.5693 · Cited by 375
Berberine pharmacology and the gut microbiota: A hidden therapeutic link
Habtemariam, S. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104722 · Cited by 352
Transforming berberine into its intestine-absorbable form by the gut microbiota
Feng, R., Shou, J.-W., Zhao, Z.-X., He, C.-Y., Ma, C., Huang, M., Fu, J., Tan, X.-S., Li, X.-Y., Wen, B.-Y., et al. (2015) · Scientific Reports · doi:10.1038/srep12155 · Cited by 307
Cicero, A. F. G., Colletti, A., Bajraktari, G., Descamps, O. S., Djuric, D. M., Владиславович, Е. М., Fras, Z., Katsiki, N., Langlois, M. R., Latkovskis, G., et al. (2017) · Nutrition Reviews · doi:10.1093/nutrit/nux047 · Cited by 303
Self-citation
Metadata
- Authors
- Derosa, G., Maffioli, P., & Cicero, A. F.
- Affiliations
- University of Pavia (IT)
- University of Bologna (IT)
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa UK Limited
- Published
- 2012-07-11
- Volume
- 12
- Issue
- 8
- Pages
- 1113-1124
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W2008978505
- Cited by
- 171
- References
- 91
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 10 · 2023: 12 · 2022: 10 · 2021: 9 · 2020: 17 · 2019: 8 · 2018: 16 · 2017: 10 · 2016: 21 · 2015: 19 · 2014: 16 · 2013: 8 · 2012: 1
- FWCI
- 1.63
- Type
- journal article
- Language
- en
- Update notices
- Open access
- closed
- Locations
- Expert Opinion on Biological Therapy (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Berberine and alkaloids research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- berberine, type 2 diabetes, hypercholesterolemia, cardiovascular disease prevention, glycemic control, lipid profile, hypolipidemic effect, anti-diabetic effects, bioavailability, drug safety, natural alkaloids
- MeSH terms
- Animals, Anticholesteremic Agents, Berberine Alkaloids, Blood Glucose, Cardiovascular Diseases, Cholesterol, Diabetes Mellitus, Type 2, Humans, Hypercholesterolemia, Hypoglycemic Agents, Risk Factors, Biomarkers, Treatment Outcome, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
